Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VRDN-003

Monoclonal antibody · Antagonist of Insulin-like growth factor 1 receptor (IGF1R) · developed by Viridian Therapeutics

Phase 3 Most advanced trial
VRDN Developer
1 Registered trials

What is VRDN-003?

VRDN-003 is a subcutaneously administered, humanized monoclonal antibody that binds the insulin-like growth factor-1 receptor (IGF-1R). It is being studied in thyroid eye disease, a condition affecting the tissues around the eye.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
Insulin-like growth factor 1 receptor (IGF1R)
Mechanism
Antagonist of Insulin-like growth factor 1 receptor (IGF1R)
Therapy area
Ophthalmology
Developer
Viridian Therapeutics, Inc. (VRDN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
XB49Z3T6CY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06812325 Phase 3 Thyroid Eye Disease (TED) Active not recruiting VRDN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Thyroid Eye Disease (TED)

Other drugs acting on IGF1R

More from Viridian Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VRDN page.

Follow VRDN, the company behind VRDN-003

See VRDN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRDN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.